JP2009536191A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536191A5
JP2009536191A5 JP2009508544A JP2009508544A JP2009536191A5 JP 2009536191 A5 JP2009536191 A5 JP 2009536191A5 JP 2009508544 A JP2009508544 A JP 2009508544A JP 2009508544 A JP2009508544 A JP 2009508544A JP 2009536191 A5 JP2009536191 A5 JP 2009536191A5
Authority
JP
Japan
Prior art keywords
compound
compound according
formula
patient
cell proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009508544A
Other languages
English (en)
Japanese (ja)
Other versions
JP5225264B2 (ja
JP2009536191A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2007/002471 external-priority patent/WO2007129226A2/en
Publication of JP2009536191A publication Critical patent/JP2009536191A/ja
Publication of JP2009536191A5 publication Critical patent/JP2009536191A5/ja
Application granted granted Critical
Publication of JP5225264B2 publication Critical patent/JP5225264B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009508544A 2006-05-09 2007-05-09 細胞増殖障害の処置 Expired - Fee Related JP5225264B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79910306P 2006-05-09 2006-05-09
US60/799,103 2006-05-09
PCT/IB2007/002471 WO2007129226A2 (en) 2006-05-09 2007-05-09 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders

Publications (3)

Publication Number Publication Date
JP2009536191A JP2009536191A (ja) 2009-10-08
JP2009536191A5 true JP2009536191A5 (enExample) 2011-09-08
JP5225264B2 JP5225264B2 (ja) 2013-07-03

Family

ID=38668152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009508544A Expired - Fee Related JP5225264B2 (ja) 2006-05-09 2007-05-09 細胞増殖障害の処置

Country Status (12)

Country Link
US (3) US20090306214A1 (enExample)
EP (1) EP2026775B1 (enExample)
JP (1) JP5225264B2 (enExample)
AU (1) AU2007246779B2 (enExample)
CA (1) CA2651375C (enExample)
DK (1) DK2026775T3 (enExample)
ES (1) ES2542344T3 (enExample)
HU (1) HUE026820T2 (enExample)
IL (1) IL195152A (enExample)
PL (1) PL2026775T3 (enExample)
PT (1) PT2026775E (enExample)
WO (1) WO2007129226A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031129A2 (en) * 2002-10-03 2004-04-15 New Era Biotech, Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
CA2560922C (en) * 2004-03-26 2014-01-07 New Era Biotech, Ltd. Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions
GB0804213D0 (en) * 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
JP2013504555A (ja) * 2009-09-09 2013-02-07 ノヴァレメッド リミテッド 疼痛の治療又は予防方法
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環式化合物及びその使用
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102787845B1 (ko) 2015-09-14 2025-03-31 트웰브 테라퓨틱스, 아이엔씨. 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1908322A (en) * 1932-04-07 1933-05-09 Claude R Cook Weed puller
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2004031129A2 (en) * 2002-10-03 2004-04-15 New Era Biotech, Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
CA2560922C (en) * 2004-03-26 2014-01-07 New Era Biotech, Ltd. Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions

Similar Documents

Publication Publication Date Title
JP2009536191A5 (enExample)
JP2010540555A5 (enExample)
CA2651375A1 (en) Treatment of cell proliferative disorders
JP2017525730A5 (enExample)
JP2012506872A5 (enExample)
JP2011057693A5 (enExample)
JP2013509429A5 (enExample)
JP2008528671A5 (enExample)
JP2008531604A5 (enExample)
JP2011504903A5 (enExample)
JP2010540556A5 (enExample)
JP2020097577A5 (enExample)
JP2011518202A5 (enExample)
JP2011046708A5 (enExample)
JP2008539267A5 (enExample)
JP2012509279A5 (enExample)
RU2011124894A (ru) Триазолотиадиазоловый ингибитор протеинкиназы с-мет
JP2017503753A5 (enExample)
JP2004531478A5 (enExample)
JP2007502832A5 (enExample)
JP2013537240A5 (enExample)
JP2018521969A (ja) 医薬用共結晶及びその用途
JP2009502777A5 (enExample)
JP2011527678A5 (enExample)
JP2012505905A5 (enExample)